Shield Therapeutics (STX) Competitors GBX 2.71 -0.01 (-0.44%) (As of 12/20/2024 12:14 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines STX vs. ELX, APC, DGI, STK, IDEA, DNL, EAH, PXS, CEL, and CHLLShould you be buying Shield Therapeutics stock or one of its competitors? The main competitors of Shield Therapeutics include El Oro (ELX), Apc Technology Group (APC), DG Innovate (DGI), StreaksAI (STK), Ideagen (IDEA), Diurnal Group (DNL), ECO Animal Health Group (EAH), Provexis (PXS), Celadon Pharmaceuticals (CEL), and Chill Brands Group (CHLL). Shield Therapeutics vs. El Oro Apc Technology Group DG Innovate StreaksAI Ideagen Diurnal Group ECO Animal Health Group Provexis Celadon Pharmaceuticals Chill Brands Group El Oro (LON:ELX) and Shield Therapeutics (LON:STX) are both small-cap manufacturing companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, community ranking, media sentiment, risk, analyst recommendations, institutional ownership and dividends. Does the media refer more to ELX or STX? In the previous week, El Oro's average media sentiment score of 0.00 equaled Shield Therapeutics'average media sentiment score. Company Overall Sentiment El Oro Neutral Shield Therapeutics Neutral Does the MarketBeat Community believe in ELX or STX? Shield Therapeutics received 162 more outperform votes than El Oro when rated by MarketBeat users. Likewise, 75.17% of users gave Shield Therapeutics an outperform vote while only 59.55% of users gave El Oro an outperform vote. CompanyUnderperformOutperformEl OroOutperform Votes5359.55% Underperform Votes3640.45% Shield TherapeuticsOutperform Votes21575.17% Underperform Votes7124.83% Do institutionals and insiders have more ownership in ELX or STX? 11.9% of Shield Therapeutics shares are held by institutional investors. 62.2% of Shield Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger earnings and valuation, ELX or STX? El Oro has higher earnings, but lower revenue than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than El Oro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEl Oro-£7.25M0.00N/A-£2.50N/AShield Therapeutics£21.47M0.99-£36.17M-£0.04-67.83 Is ELX or STX more profitable? El Oro has a net margin of 0.00% compared to Shield Therapeutics' net margin of -168.42%. El Oro's return on equity of 0.00% beat Shield Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets El OroN/A N/A N/A Shield Therapeutics -168.42%-261.67%-47.85% SummaryShield Therapeutics beats El Oro on 6 of the 10 factors compared between the two stocks. Ad Stansberry Research2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisisDan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.Click here to see Dan's full warning to the public. Get Shield Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STX vs. The Competition Export to ExcelMetricShield TherapeuticsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£21.22M£1.17B£5.14B£1.90BDividend YieldN/A3.04%5.09%5.55%P/E Ratio-67.83131.2389.741,818.01Price / Sales0.991,981.001,117.09385,452.11Price / Cash6.3610.2543.1028.51Price / BookN/A3.084.782.78Net Income-£36.17M£152.21M£120.31M£157.16M7 Day Performance-1.35%-0.48%-1.92%-2.00%1 Month Performance-4.81%-1.88%13.65%21.18%1 Year Performance-57.94%98.32%28.34%29.10% Shield Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STXShield TherapeuticsN/AGBX 2.71-0.4%N/A-57.9%£21.22M£21.47M-67.8340,000ELXEl OroN/AGBX 65flatN/AN/A£41.06M£-7,248,605.00-26.001,122APCApc Technology GroupN/AGBX 9.88flatN/AN/A£18.03M£19.20M19.75164,000DGIDG InnovateN/AGBX 0.08-4.7%N/A-51.6%£9.64M£24,500.00-1.25790STKStreaksAIN/AGBX 1.14-5.0%N/A+35.3%£4.32MN/A-32.503Gap DownHigh Trading VolumeIDEAIdeagenN/AGBX 349-0.3%N/AN/A£1.03B£75.28M17,450.009DNLDiurnal GroupN/AGBX 27.30flatN/A+0.0%£46.33M£4.68M-3.2133EAHECO Animal Health GroupN/AGBX 68.14-2.7%N/A-37.1%£46.16M£89.42M3,450.00234Gap DownPXSProvexisN/AGBX 0.65+4.8%N/A+18.2%£14.69M£426,168.0043.754Gap DownCELCeladon PharmaceuticalsN/AGBX 18.95-9.8%N/A-87.5%£13.05M£11,258.00-237.502,780News CoverageGap DownCHLLChill Brands GroupN/AN/AN/AN/A£10.89M£624,187.00-215.007News Coverage Related Companies and Tools Related Companies ELX Competitors APC Competitors DGI Competitors STK Competitors IDEA Competitors DNL Competitors EAH Competitors PXS Competitors CEL Competitors CHLL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:STX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shield Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Shield Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STX Stock Alerts